Journal ArticleDOI
Outcome of childhood acute lymphoblastic leukemia with induction failure treated by the Japan Association of Childhood Leukemia Study (JACLS) ALL F-protocol
Nobuhiro Suzuki,Keiko Yumura-Yagi,Makoto Yoshida,Junichi Hara,Shin-Ichiro Nishimura,Tooru Kudoh,Akio Tawa,Ikuya Usami,Akihiko Tanizawa,Hiroki Hori,Yasuhiko Ito,Ryosuke Miyaji,Megumi Oda,Koji Kato,Kazuko Hamamoto,Yuko Osugi,Yoshiko Hashii,Tatsutoshi Nakahata,Keizo Horibe +18 more
TLDR
Children with acute lymphoblastic leukemia who fail to achieve complete remission (CR) after induction therapy (induction failure: IF) have a poor prognosis; however, there have been few prospective studies in patients with IF.Abstract:
Background
Children with acute lymphoblastic leukemia (ALL) who fail to achieve complete remission (CR) after induction therapy (induction failure: IF) have a poor prognosis; however, there have been few prospective studies in patients with IF.
Patients and Methods
Between April 1997 and March 2005, 27 of 1,237 leukemic patients (2.2%) failed to achieve CR after four- or five-drug induction therapy. Twenty-three of these patients entered the F-protocol study, which mainly consisted of acute-myeloid-leukemia-oriented chemotherapy followed by scheduled hematopoietic cell transplantation (HCT).
Results
Seventeen (73.9%) of the 23 patients responded to re-induction chemotherapy with CR. Of note, 15 (93.8%) of 16 patients with Philadelphia-chromosome-negative (non-Ph+) ALL achieved CR; in contrast, only 2 (28.6%) of 7 Ph+ patients achieved CR. Fourteen (82.4%) of 17 patients remained in CR (CCR) until their scheduled HCT, 12 of the 14 with CCR underwent HCT as scheduled, and 6 patients remain in first CR after a median of 78 months (range, 49–107 months). The 5-year overall survival (OS) rates of 16 patients with non-Ph+ and 7 patients with Ph+ were 43.8 ± 12.4% and 14.3 ± 13.2%, respectively (P = 0.012). The 5-year OS rate of the 17 patients who obtained CR by re-induction therapy and the 6 who did not were 47.1 ± 12.1% and 0%, respectively (P < 0.001).
Conclusion
Acute-myeloid-leukemia-oriented chemotherapy followed by scheduled HCT is a promising treatment strategy for non-Ph+ ALL patients with IF. Pediatr Blood Cancer 2010; 54:71–78. © 2009 Wiley-Liss, Inc.read more
Citations
More filters
Journal ArticleDOI
MEF2D-BCL9 Fusion Gene Is Associated With High-Risk Acute B-Cell Precursor Lymphoblastic Leukemia in Adolescents
Kyogo Suzuki,Yusuke Okuno,Nozomu Kawashima,Hideki Muramatsu,Tatsuya Okuno,Xinan Wang,Shinsuke Kataoka,Yuko Sekiya,Motoharu Hamada,Norihiro Murakami,Daiei Kojima,Kotaro Narita,Atsushi Narita,Hirotoshi Sakaguchi,Kimiyoshi Sakaguchi,Nao Yoshida,Nobuhiro Nishio,Asahito Hama,Yoshiyuki Takahashi,Kazuko Kudo,Koji Kato,Seiji Kojima +21 more
TL;DR: A novel MEF2D-BCL9 fusion is identified that characterizes a novel subset of pediatric ALL, predicts poor prognosis, and may be a candidate for novel molecular targeting.
Journal ArticleDOI
Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor acute lymphoblastic leukemia.
Naoto Morishita,Hirokazu Tsukahara,Kosuke Chayama,Toshiaki Ishida,Kana Washio,Takako Miyamura,Nobuko Yamashita,Megumi Oda,Tsuneo Morishima +8 more
TL;DR: This study was undertaken to explore the clinical relevance and molecular mechanisms underlying the activation of Akt (i.e., phosphorylated Akt, P‐Akt) in pediatric B‐pre ALL.
Journal ArticleDOI
IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan
Daisuke Asai,Toshihiko Imamura,So-ichi Suenobu,Akiko Saito,Daiichiro Hasegawa,Takao Deguchi,Yoshiko Hashii,Kimikazu Matsumoto,Hirohide Kawasaki,Hiroki Hori,Akihiro Iguchi,Yoshiyuki Kosaka,Koji Kato,Keizo Horibe,Keiko Yumura-Yagi,Junichi Hara,Megumi Oda +16 more
TL;DR: IKZF1 deletion was identified as adverse prognostic factor even in pediatric BCP‐ALL in NCI‐HR showing good response to PSL, and JAK2 mutations and P2RY8‐CRLF2 fusion were rarely detected.
Journal ArticleDOI
Characterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan.
Toshihiko Imamura,Nobutaka Kiyokawa,Motohiro Kato,Chihaya Imai,Yasuhiro Okamoto,Mio Yano,Kentaro Ohki,Yuki Yamashita,Yuichi Kodama,A M Saito,Mayumi Mori,Sae Ishimaru,Takao Deguchi,Yoshiko Hashii,Yasuto Shimomura,Toshinori Hori,Keisuke Kato,Hiroaki Goto,Chitose Ogawa,Katsuyoshi Koh,Tomohiko Taki,Ayumu Manabe,Atsushi Sato,Atsushi Kikuta,S. Adachi,K Horibe,Akira Ohara,Akira Watanabe,Yoshifumi Kawano,Eiichi Ishii,Hiroyuki Shimada +30 more
TL;DR: The outcome was not satisfactory without sophisticated minimal residual disease-based stratification and the efficacy of TKIs combined with conventional chemotherapy without allogeneic hematopoietic stem cell transplantation in this cohort should be determined.
References
More filters
Journal ArticleDOI
Treatment of acute lymphoblastic leukemia.
Ching-Hon Pui,William E. Evans +1 more
TL;DR: This review considers recent advances in the treatment of ALL, emphasizing issues that need to be addressed if treatment outcome is to improve further.
Journal ArticleDOI
Transplants of Umbilical-Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute Leukemia
Vanderson Rocha,Myriam Labopin,Guillermo Sanz,William Arcese,Rainer Schwerdtfeger,Alberto Bosi,Niels Jacobsen,Tapani Ruutu,Marcos de Lima,Jürgen Finke,Francesco Frassoni,Eliane Gluckman +11 more
TL;DR: Cord blood from an unrelated donor is an alternative source of hematopoietic stem cells for adults with acute leukemia who lack an HLA-matched bone marrow donor.
Journal ArticleDOI
Outcomes after Transplantation of Cord Blood or Bone Marrow from Unrelated Donors in Adults with Leukemia
Mary J. Laughlin,Mary Eapen,Pablo Rubinstein,John E. Wagner,Mei Jei Zhang,Richard E. Champlin,Cladd E. Stevens,Juliet N. Barker,Robert Peter Gale,Hillard M. Lazarus,David I. Marks,Jon J. van Rood,Andromachi Scaradavou,Mary M. Horowitz +13 more
TL;DR: HLA-mismatched cord blood should be considered an acceptable source of hematopoietic stem-cell grafts for adults in the absence of an HLA-matched adult donor.
Journal ArticleDOI
Treatment of Acute Lymphoblastic Leukemia
TL;DR: The treatment of acute lymphoblastic leukemia in the last decade has reached a revolutionary phase and the well-informed investigator is employing acute leukemia protocols which are aimed at cure rather than palliation.
Related Papers (5)
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study
Monique L. den Boer,Marjon van Slegtenhorst,Renee X. de Menezes,Renee X. de Menezes,Meyling Cheok,Jessica Buijs-Gladdines,Susan T C J M Peters,Laura J. C. M. van Zutven,H. Berna Beverloo,Peter J. van der Spek,Gaby Escherich,Martin A. Horstmann,Gritta Janka-Schaub,Willem A. Kamps,William E. Evans,Rob Pieters +15 more